To Meta-analyze the efficacy and safety of Yangxinshi Tablets in the treatment of chest pain after percutaneous coronary intervention(PCI) to provide a reference for its clinical application.Methods:CNKI,CSPD,CCD,China Biology Medicine disc,PubMed,Embase,Web of Science,and Cochrane Library were searched for randomized controlled trials(RCTs) on Yangxinshi Tablets in the treatment of chest pain after PCI according to the search strategy and inclusion and exclusion criteria from database inception to August 2021.Cochrane risk-of-bias tool and modified Jadad scale were used to evaluate the quality of included RCTs.Meta-analysis was carried out by RevMan 5.3.Results:Eight research articles were included,with 697 patients involved,including 349 patients in the Yangxinshi Tablets group,and 348 in the control group.Literature quality evaluation showed 4 points for five articles and 3 points for three articles.Meta-analysis showed that the Yangxinshi Tablets group was effective in the treatment of chest pain after PCI［6 RCTs,n=505; RR(95%CI)＝1.29(1.16 to 1.42)，P<0.001］,and had the trend of improving traditional Chinese medicine(TCM) syndrome after PCI［2 RCTs,n=149; RR(95%CI)＝1.56(0.85 to 2.85)，P=0.15］.Additionally,the Yangxinshi Tablets group could also improve the ST-segment depression amplitude of ECG 7 days after PCI［2 RCTs,n=163; MD(95%CI)＝0.07(0.05 to 0.09)，P<0.001］,reduce the incidence of major adverse cardiovascular events after PCI［2 RCTs,n=163,RR(95%CI)=0.41(0.25 to 0.70),P<0.001］,and increase the 6-min walking distance after PCI［2 RCTs,n=150; MD(95%CI)＝80.30,(23.12 to 137.47)，P<0.01］.There was no increase in the incidence of adverse events［2 RCTs,n=198,RR(95%CI)=1.35(0.77 to 2.37),P=0.29］.Conclusion:Yangxinshi Tablets combined with conventional western medicine can improve chest pain after PCI with good safety.More high-quality research is encouraged to provide evidence for the clinical application of Yangxinshi Tablets.